Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A
Haemophilia · 2024
DOI: 10.1111/hae.15025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2024. Verfasst von Suresh Agarwal und 8 weiteren Autor:innen. Beteiligte Einrichtung: BioMarin Pharmaceutical Inc., Novato, California, USA. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Factor VIII. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BioMarin Pharmaceutical Inc., BioMarin Pharmaceutical.
Abstract (Originalsprache)
Introduction
Valoctocogene roxaparvovec, a gene therapy evaluated in the phase 3 GENEr8‐1 trial, supports endogenous factor VIII (FVIII) production to prevent bleeding in people with severe haemophilia A. Individuals receiving emicizumab, an antibody mimicking the function of activated FVIII, were excluded from GENEr8‐1 enrolment since emicizumab was an investigational therapy at the time of trial initiation.
Aim
Utilize pharmacokinetic simulations to provide guidance on best practices for maintaining haemostatic control while transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec.
Methods
To estimate bleeding risk at weekly intervals following valoctocogene roxaparvovec infusion, a published emicizumab pharmacokinetic model was used to simulate emicizumab concentrations and merged with FVIII activity time‐course data for participants in GENEr8‐1. The analysis investigated three approved emicizumab dosing regimens for two transition scenarios that varied whether the last dose of emicizumab was administered on the same day or 4 weeks after valoctocogene roxaparvovec infusion.
Results
Simulations demonstrated administering the last emicizumab dose the day of valoctocogene roxaparvovec infusion and 4 weeks after offered similar levels of haemostatic control, and bleeding risk was similar for all emicizumab dosing regimens. An algorithm was developed to provide guidance for discontinuation of emicizumab. Theoretical cases based on GENEr8‐1 participants are presented to illustrate how decisions may vary among individuals.
Conclusion
Pharmacokinetic simulations demonstrated no clinically meaningful difference in bleeding risk caused by decaying emicizumab levels and rising gene therapy‐derived endogenous FVIII for all examined emicizumab doses and dosing regimens. Therefore, multiple approaches can safely transition individuals from emicizumab prophylaxis to valoctocogene roxaparvovec.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BioMarin Pharmaceutical Inc., Novato, California, USA.
- Division of Adult Haematology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
- Medical Clinic 2, University Hospital Frankfurt, Frankfurt, Germany.
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy.
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
- Hemostasis and Thrombosis Program, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA.
ORCID-Profile: Wolfgang Miesbach, Flora Peyvandi, Robert Sidonio, Steven Pipe
Förderung
- BioMarin Pharmaceutical Inc.
- BioMarin Pharmaceutical
Zitieren
APA
Agarwal, S., Hermans, C., Miesbach, W., Peyvandi, F., Sidonio, R., Osmond, D., Newman, V., Henshaw, J., & Pipe, S. (2024). Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A. Haemophilia. https://doi.org/10.1111/hae.15025
Vancouver
Agarwal S, Hermans C, Miesbach W, Peyvandi F, Sidonio R, Osmond D, et al. Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A. Haemophilia. 2024. doi:10.1111/hae.15025
BibTeX
@article{Agarwal2024,
author = {Agarwal, Suresh and Hermans, Cedric and Miesbach, Wolfgang and Peyvandi, Flora and Sidonio, Robert and Osmond, Dane and Newman, Vanessa and Henshaw, Josh and Pipe, Steven},
title = {Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A},
journal = {Haemophilia},
year = {2024},
doi = {10.1111/hae.15025}
}
EUVIMED